Publications by authors named "G G Bebb"
Article Synopsis
- DLL3 is a key target for therapy in small cell lung cancer (SCLC) due to its high expression, which is present in about 15% of all lung cancer cases.
- A systematic literature review analyzed various studies to determine how often DLL3 is expressed in SCLC, using methods like immunohistochemistry to measure its prevalence and impact on treatment response and patient survival.
- Results from 30 studies showed a high prevalence of DLL3 positivity, with variation depending on the thresholds used; however, no consistent links were found between DLL3 levels and patient demographics or disease stage.
Genome-wide Detection of Chimeric Transcripts in Early-stage Non-small Cell Lung Cancer.
Cancer Genomics Proteomics
November 2023
Background/aim: Lung cancer remains the main culprit in cancer-related mortality worldwide. Transcript fusions play a critical role in the initiation and progression of multiple cancers. Treatment approaches based on specific targeting of discovered driver events, such as mutations in EGFR, and fusions in NTRK, ROS1, and ALK genes led to profound improvements in clinical outcomes.
View Article and Find Full Text PDFArticle Synopsis
- * DLL3 is a promising target for SCLC treatment since it is largely overexpressed in cancer cells but minimally present in normal cells; research is ongoing into various DLL3-targeted therapies like antibody-drug conjugates, T-cell engagers, and CAR T-cell therapies.
- * The clinical failure of a DLL3-targeting treatment called rovalpituzumab tesirine (Rova-T) highlights the need for continued development and refinement of DLL3-targeting strategies, focusing on patient selection and combination therapies to improve effectiveness.
(1) Background: As genomic testing is becoming a part of the mainstream oncology practice, it is vital to ensure that our patients fully understand the implications of these tests. This study aimed to compare the attitudes and expectations of cancer patients with those of their physicians regarding the role of biomarker testing in clinical decision making. (2) Methods: Two separate, complimentary, self-administered questionnaires for patients with cancer and their physicians, respectively, were collected in Calgary, Alberta, Canada.
View Article and Find Full Text PDFIntroduction: New requirements in Canada's pricing processes for patented drugs may exacerbate delays in regulatory and reimbursement reviews. This study seeks to better understand the impact of any additional delays on non-small cell lung cancer (NSCLC) patients by measuring the following: (a) durations and outcomes of regulatory and reimbursement reviews of NSCLC drugs in Canada and reference countries; (b) delays in Canada's reviews of three NSCLC drugs (nivolumab, afatinib, and pemetrexed [NAP]); and (c) estimating clinical, patient, and economic impacts of delays in Canada's reviews on access to NAP.
Methods: Information from the Context Matters database and the literature (2005-2020) was used to evaluate the durations and outcomes of reimbursement reviews of NSCLC drugs in Canada and comparator countries.